No Data
No Data
Foghorn Therapeutics (FHTX) Collaborates With Eli Lilly and Surpasses Q3 Expectations
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences
Express News | Foghorn Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q3 EPS Results
H.C. Wainwright Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating, Maintains Target Price $20
TD Cowen Maintains Foghorn Therapeutics(FHTX.US) With Buy Rating
TD Cowen Keeps Their Buy Rating on Foghorn Therapeutics (FHTX)
loading...
loading...
No Data
No Data